These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17898787)

  • 21. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC
    Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
    Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
    Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
    Lefrère F; Delmer A; Suzan F; Levy V; Belanger C; Djabarri M; Arnulf B; Damaj G; Maillard N; Ribrag V; Janvier M; Sebban C; Casasnovas RO; Bouabdallah R; Dreyfus F; Verkarre V; Delabesse E; Valensi F; McIntyre E; Brousse N; Varet B; Hermine O
    Leukemia; 2002 Apr; 16(4):587-93. PubMed ID: 11960337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].
    Takasaki H; Hashimoto C; Takemura S; Motomura S; Ishigatsubo Y
    Rinsho Ketsueki; 2010 Jan; 51(1):57-62. PubMed ID: 20134141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
    Paoluzzi L; Scotto L; Marchi E; Seshan VE; O'Connor OA
    Br J Haematol; 2009 Sep; 146(6):656-9. PubMed ID: 19604235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
    Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
    Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
    Orciuolo E; Buda G; Pelosini M; Petrini M
    Br J Haematol; 2010 Mar; 148(5):810-2. PubMed ID: 19919649
    [No Abstract]   [Full Text] [Related]  

  • 29. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
    Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
    Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
    Milani V; Lorenz M; Weinkauf M; Rieken M; Pastore A; Dreyling M; Issels R
    Int J Hyperthermia; 2009 Jun; 25(4):262-72. PubMed ID: 19670095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
    Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
    Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current treatment approaches for mantle-cell lymphoma.
    Witzig TE
    J Clin Oncol; 2005 Sep; 23(26):6409-14. PubMed ID: 16155027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
    Jung HJ; Chen Z; McCarty N
    Am J Hematol; 2012 Dec; 87(12):1057-64. PubMed ID: 22965904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
    N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
    An J; Sun Y; Fisher M; Rettig MB
    Leukemia; 2004 Oct; 18(10):1699-704. PubMed ID: 15343345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
    Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
    Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment.
    Venkataraman G; Maududi T; Ozpuyan F; Bahar HI; Izban KF; Qin JZ; Alkan S
    Leuk Res; 2006 Nov; 30(11):1377-84. PubMed ID: 16624404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.